Thalys Medical Technology Group

Thalys Medical Technology Group EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Thalys Medical Technology Group (603716.SS) as of Nov 3, 2026 is -58.04 M CNY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -74.31 M CNY — a change of -21.90% (higher).

EBITDA

-58.04 MCNY

YoY

-21.90%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Thalys Medical Technology Group is 2025 -58.04 M CNY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Thalys Medical Technology Group was 2024 -74.31 M CNY. It decreases by -21.90% higher compared to the previous year.

The Thalys Medical Technology Group EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
166.14 M CNY
Jan 1, 2019
198.06 M CNY
Jan 1, 2020
132.64 M CNY
Jan 1, 2021
77.63 M CNY
Jan 1, 2022
-76.84 M CNY
Jan 1, 2023
-96.59 M CNY
Jan 1, 2024
-74.31 M CNY
Jan 1, 2025
-58.04 M CNY
The Thalys Medical Technology Group EBITDA history
YEAREBITDAYoY
-58.04 MCNY-21.90%
-74.31 MCNY-23.06%
-96.59 MCNY+25.71%
-76.84 MCNY-198.98%
77.63 MCNY-41.48%
132.64 MCNY-33.03%
198.06 MCNY+19.21%
166.14 MCNY+8.37%
153.30 MCNY+46.23%
104.84 MCNY+23.30%
85.03 MCNY+8.54%
78.34 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Thalys Medical Technology Group Stock analysis

What does Thalys Medical Technology Group do? Thalys Medical Technology Group Corp, based in Wuhan, China, operates in the Health Care sector with a focus on Biotechnology. The company develops, produces, and sells in vitro diagnostic products, including reagents, consumables, and equipment. It serves major domestic markets such as Hubei, Hunan, Jiangsu, Henan, and Shanghai, employing 1,474 full-time staff. Listed on October 31, 2016, Thalys specializes in diagnostic solutions for the Chinese healthcare market. Thalys Medical Technology Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Thalys Medical Technology Group stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Thalys Medical Technology Group is -58.04 M CNY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Thalys Medical Technology Group changed from -74.31 M CNY to -58.04 M CNY, representing a -21.90% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Thalys Medical Technology Group since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Thalys Medical Technology Group historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Thalys Medical Technology Group

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Thalys Medical Technology Group